From the Journals

GLP-1–Progestin and Endometrial Cancer Risk

Adjunct therapy tied to fewer cancers and hysterectomies.

Share

  • 1

    Study published in JAMA Network Open.

  • 2

    Focused on GLP-1 RAs and progestins for endometrial cancer risk.

  • 3

    Analyzed data from over 400,000 women.

  • 4

    Significant reduction in cancer risk noted.

  • 5

    Lower hysterectomy incidence at 2 and 5 years.

  • 6

    Importance of treating hormonal/metabolic risks in obese women.

  • 7

    Further studies recommended for validation.

Original Source(s)

GLP-1–Progestin and Endometrial Cancer Risk

Adjunct therapy tied to fewer cancers and hysterectomies.

  • by Julia Cipriano, MS, CMPP

  • March 2, 2026

  • 3 min

Related Content

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

Exercise Matters Following Cancer

Postdiagnosis physical activity was associated with lower cancer mortality across several cancer types.

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.